GlassScriptPhysician profile
Mathew M Wehbe
NPI 1619186368
$119,900.58
in general payments reported to CMS, 2019-2025
10 companies · $45K in 2025
The $45K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.23 · 2021: $1,387 · 2022: $5,387 · 2023: $33K · 2024: $35K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100K · Travel and Lodging: $9,746 · Food and Beverage: $2,891 · Education: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,434.00 |
| Travel and Lodging | $9,746.13 |
| Food and Beverage | $2,891.14 |
| Education | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $90,363.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $29,053.80 | 2024-2025 | Datroway, Tagrisso, Imfinzi |
| Myriad Genetic Laboratories, INC. | $269.34 | 2023-2025 | Myrisk |
| Janssen Biotech, INC. | $59.87 | 2024 | Erleada, Akeega, Rybrevant |
| Aveo Pharmaceuticals, INC. | $40.00 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $39.85 | 2025 | Lynozyfic |
| Dendreon Pharmaceuticals LLC | $32.09 | 2024 | Provenge |
| Astellas Pharma US INC | $15.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.71 | 2024 | Opdivo |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Wehbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.